Abstract
It is well demonstrated that inflammatory processes in the interstitium are pivotal as the pathological features of idiopathic interstitial pneumonia (IIP). Standard therapy with corticosteroids may suppress such inflammatory changes, but not result in marked clinical benefits, especially among patients with idiopathic pulmonary fibrosis (IPF). Recent studies clarified that the degrees of cell infiltration did not correlate with the clinical outcomes, but so-called remodeling processes, such as the number of fibroblastic foci, can more accurately predict the life expectancy among patients with IPF; the most common disease entity with poor prognosis. In accordance with such findings, anti-inflammatory strategies including treatment with corticosteroids, immunosuppressive agents, and even recently studied agent interferon-gamma have not been successful to stop or improve this process. More focuses should be now cast onto the molecular processes of myofibroblastic differentiation, proliferation and apoptosis of lung fibroblasts. Agents regulating these processes may become new therapeutic choices for these progressive pulmonary disorders.
Keywords: idiopathic interstitial pneumonia, idiopathic pulmonary fibrosis, lung remodeling, fibroblastic foci, myofibroblast, signal transduction
Current Respiratory Medicine Reviews
Title: Lung Remodeling in Interstitial Pneumonia: A New Molecular Target of Pulmonary Fibrosis
Volume: 1 Issue: 1
Author(s): Mitsuhiro Sunohara and Hajime Takizawa
Affiliation:
Keywords: idiopathic interstitial pneumonia, idiopathic pulmonary fibrosis, lung remodeling, fibroblastic foci, myofibroblast, signal transduction
Abstract: It is well demonstrated that inflammatory processes in the interstitium are pivotal as the pathological features of idiopathic interstitial pneumonia (IIP). Standard therapy with corticosteroids may suppress such inflammatory changes, but not result in marked clinical benefits, especially among patients with idiopathic pulmonary fibrosis (IPF). Recent studies clarified that the degrees of cell infiltration did not correlate with the clinical outcomes, but so-called remodeling processes, such as the number of fibroblastic foci, can more accurately predict the life expectancy among patients with IPF; the most common disease entity with poor prognosis. In accordance with such findings, anti-inflammatory strategies including treatment with corticosteroids, immunosuppressive agents, and even recently studied agent interferon-gamma have not been successful to stop or improve this process. More focuses should be now cast onto the molecular processes of myofibroblastic differentiation, proliferation and apoptosis of lung fibroblasts. Agents regulating these processes may become new therapeutic choices for these progressive pulmonary disorders.
Export Options
About this article
Cite this article as:
Sunohara Mitsuhiro and Takizawa Hajime, Lung Remodeling in Interstitial Pneumonia: A New Molecular Target of Pulmonary Fibrosis, Current Respiratory Medicine Reviews 2005; 1 (1) . https://dx.doi.org/10.2174/1573398052953686
DOI https://dx.doi.org/10.2174/1573398052953686 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms of Altered Cell Immunity and Cytotoxicity in COPD
Current Drug Targets Inflammasome Activation in Chronic Glomerular Diseases
Current Drug Targets Immunomodulatory Effects of Endogenous and Synthetic Peptides Activating Opioid Receptors
Mini-Reviews in Medicinal Chemistry Hyperglycemia-Related Pathophysiologic Mechanisms and Potential Beneficial Actions of Melatonin
Mini-Reviews in Medicinal Chemistry Non-Invasive Tests in Animal Models and Humans: A New Paradigm for Assessing Efficacy of Biologics Including Prebiotics and Probiotics
Current Pharmaceutical Design Mucosal Vaccines: Where Do We Stand?
Current Topics in Medicinal Chemistry Bortezomib in the Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Interleukin-12: An Update on its Immunological Activities, Signaling and Regulation of Gene Expression
Current Immunology Reviews (Discontinued) Development and in vitro Evaluation of Diclofenac Sodium Loaded Mucoadhesive Microsphere with Natural Gum for Sustained Delivery
Current Drug Delivery Development of Antibacterial Drugs by Targeting Toll-Like Receptors
Current Topics in Medicinal Chemistry Role of Metalloproteinases in Tendon Pathophysiology
Mini-Reviews in Medicinal Chemistry Interrelated Roles for the Aryl Hydrocarbon Receptor and Hypoxia Inducible Factor-1α in the Immune Response to Infection
Current Immunology Reviews (Discontinued) Cancer Immunotherapy Using Gene-Modified Dendritic Cells
Current Gene Therapy Myocardial Protection Against Ischemia-Reperfusion Injury: Novel Approaches in Maintaining Homeostatic Stability in Blood
Recent Patents on Cardiovascular Drug Discovery Strategic Aspects of NPY-Based Monoclonal Antibodies for Diagnosis and Treatment of Breast Cancer
Current Protein & Peptide Science Studies of p53 Tumor Suppression Activity in Mouse Models
Current Genomics Minocycline Increases in-vitro Cortical Neuronal Cell Survival after Laser Induced Axotomy
Current Clinical Pharmacology Therapeutic Targeting of TRPV1 by Resiniferatoxin, from Preclinical Studies to Clinical Trials
Current Topics in Medicinal Chemistry The Potential Prognostic, Diagnostic and Therapeutic Targets for Recurrent Arrhythmias in Patients with Coronary Restenosis and Reocclusions After Coronary Stenting
Current Pharmaceutical Design Natural Therapies of the Inflammatory Bowel Disease: The Case of Rutin and its Aglycone, Quercetin
Mini-Reviews in Medicinal Chemistry